Amneal Pharmaceuticals (NASDAQ:AMRX) posted fourth-quarter net revenue of $814 million on Friday, exceeding Wall Street’s consensus estimate of $806 million.
The Bridgewater, N.J.-based company reported GAAP net income of $35 million, or $0.11 per diluted share, as it continues its strategic transition from commodity generics toward high-value complex medicines.
For the full year 2025, the company crossed the $3 billion revenue threshold, finishing at $3.02 billion with a total GAAP net profit of $72 million.
On an adjusted basis, full-year diluted earnings reached $0.83 per share.
Growth was primarily fueled by the company’s Specialty segment, including the Parkinson’s therapy CREXONT and UNITHROID, alongside strong performance from its AvKARE distribution business.
Management provided an optimistic outlook for 2026, initiating revenue guidance between $3.05 billion and $3.15 billion.
The company expects adjusted EBITDA to land between $720 million and $760 million, with adjusted diluted EPS forecasted at $0.93 to $1.03—suggesting double-digit bottom-line growth.